Citius Pharmaceuticals, Inc. CTXR
Set alert
0.52 USD -0.04 -7.10%
At close
0.52 0.00 -0.59%
Pre-market · Nov 2, 4:06 AM ET
0.5207 Day range 0.564
0.37 52-week range 1.60
- YTD
- -32.68%
- 1 year
- -66.68%
- Open
- 0.564
- Prev close
- 0.5631
- Mkt cap
- 14.36M
- Vol
- 104.67K
- Avg vol
- 472.24K
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5207
- High
- 0.564
- Forward P/E
- 15.32
- Beta
- 1.66
- Short ratio
- 1.23
- Inst. own
- 13.17%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 3, 2025
- 50-d avg
- 6.51
- 200-d avg
- 14.50
- 1y target
- 54.00
News
6 days ago gurufocus.com
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIRÂ Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2
-
6 days ago benzinga.com
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
itius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius
6 days ago prnewswire.com
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of…